Dr. Zeil Rosenberg is a physician-executive with expertise in immunization programs and vaccines, immunotherapeutics, medical devices, infectious diseases and disaster preparedness. He currently serves as Managing Director at BioVance Medical LLC, provides strategic advisory services to life sciences companies. He served as CEO of Immuron LLC, a biopharmaceuticals company developing antibodies to address infectious and chronic diseases (pediatric diarrheal diseases, influenza, HIV/AIDS ) . Prior to that, Dr. Rosenberg served as Worldwide Business Leader and Medical Director at Becton Dickinson & Co.(BD) where he was responsible for new vaccine delivery technologies to improve immunization programs worldwide. Prior to that, Dr. Rosenberg was Director, Family Health in the NY State Health Department; Director, National Programs at the Children's Health Fund; National Immunization Advisor for the Ministry of Health, Indonesia; AAAS Science and Diplomacy Fellow at USAID in Washington, DC. serving as Chief Technical Officer for its global immunization initiative. Dr Rosenberg has a long history of collaboration with a wide range of international non-governmental health organizations.
Education & Training:
MPH, , 1985
MD, UCSF, 1982
BA, Stanford University, 1978
Specialty Fellow, American Academy of Pediatrics
Fellow, American College of Preventive Medicine
Fellow, NY Academy of Medicine
Former Chairperson, ACPM Terrorism and Emergency Preparedness Commitee
Member and former Treasurer, Global Health Council
Selected Global Activities:
Dr. Rosenberg works with researchers to develop immunotherapeutics, including medical foods, that can help reduce GI microbial translocation and improve immune status in patients with HIV/AIDS, sepsis and severe malnutrition. He is a recognized expert in safe immunization and other injection technologies to improve vaccine efficacy and safety.
Dr. Rosenberg works to develop novel solutions for orally delivered, passive immune protection against influenza as well has expertise in mass immunization in community and institutional settings.
Medical Devices and
Dr. Rosenberg is involved in Medical Device development working with collaborating companies. The devices, under clinical study in the US, Israel and elsewhere, address othopedics, radiation therapy, chronic gastrointestinal diseases.
Rosenberg Z "Translational Challenges: From Immunology to Public Health" Foundation Merieux. Annecy, France Conference on Innate and Adaptive Immunity After Transcutaneous or Mucosal Vaccination 2004
Rosenberg Z, Fuerst,O, Pripstein L "National Immunization Conference" "Use of Mobile, Advanced Clinical Information System to Address Influenza Pandemic Preparedness" Atlanta US Centers for Disease Control and Prevention 2004
Rosenberg Z "Conference on Needle Free Injection" "Alternative Immunization Delivery Technologies" Crystal City,VA National Foundation for Infectious Diseases 1999
Lonsari R and Rosenberg Z "Tetanus toxoid immunization of prospective brides in Central Java, Indonesia" Health Policy and Planning 4:3 235-38 1989
Rosenberg Z, Findley S, McPhillips S, et.al "Community based strategies for immunizing the "Hard-to-Reach" Child." American Journal of Preventive Medicine 11 :(suppl 1) 14-20 1995
Rosenberg Z "Medical Technologies for Biodefense Vaccine Development and Agent Detection" "Medical Technologies for Biodefense Vaccine Development and Agent Detection" Washington,DC Biodefense Vaccines, Therapeutics and Diagnostics Conference 2004